Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
Pfizer
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
ViroMissile, Inc.
Replimune Inc.
Tizona Therapeutics, Inc
AgonOx, Inc.
Novartis
Degron Therapeutics Co.
University Health Network, Toronto
The First Affiliated Hospital of Xinxiang Medical College
Petrov, Andrey
AstraZeneca
Guangzhou FineImmune Biotechnology Co., LTD.
M.D. Anderson Cancer Center
Thomas Jefferson University
Columbia University
Revolution Medicines, Inc.
Novartis
National Cancer Institute (NCI)
Checkpoint Therapeutics, Inc.
ABM Therapeutics Corporation
Inhibrx Biosciences, Inc
National Cancer Institute (NCI)
Celldex Therapeutics
University of California, San Francisco
R-Pharm
AO GENERIUM
National Cancer Institute (NCI)
Fate Therapeutics
Cantargia AB
Prelude Therapeutics
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Provectus Pharmaceuticals
Revolution Medicines, Inc.
Imperial College London
Pfizer
Incyte Corporation
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
BioNTech SE
Asana BioSciences
Lumos Pharma
Celgene